Literature DB >> 26417965

Emergency Hospital Care for Exacerbation of COPD: Is Inhaled Maintenance Therapy Modified?

Xavier Pomares1,2,3, Concepción Montón1,4, Marisa Baré5,6,4, Marina Pont5,4, Cristina Estirado7, Joaquim Gea7,3, José Maria Quintana8,4, Silvia Vidal9, Ana Santiago10.   

Abstract

BACKGROUND: The impact of hospital emergency care and inward admission for acute exacerbations of COPD on inhaled maintenance treatment is not well known.
OBJECTIVE: Therefore, we evaluated the impact of short-stay emergency hospital care and inward admission for acute exacerbation of COPD (eCOPD) on inhaled maintenance treatment prescribed at discharge.
DESIGN: Prospective observational cohort study of patients presenting with eCOPD at emergency departments in 16 hospitals of the Spanish healthcare system. The ethics committee at each hospital approved the study and patients provided an informed consent before inclusion. We classified the patients according to the severity of COPD: mild/moderate (FEV1 ≥ 50% predicted) or severe/very severe (FEV1 < 50% predicted) and need of inward hospitalisation. We analysed changes to maintenance treatment on discharge according to GOLD strategy.
RESULTS: 1559 patients, 65% required hospitalisation. The most common maintenance treatment was inhaled corticoids (ICS) (80.9%) followed by long-acting beta-agonists (LABA) (75.4%). The most common combination was triple therapy (LABA+ LAMA+ICS) (56.2%) followed by LABA+ICS dual therapy (18.2%) regardless of the severity of COPD. In more than 60% of patients treatment was not changed at discharge. The most common change in treatment was a reduction when discharge was from emergency care and an increase after hospitalisation (-21.6% and +19.5% in severe/very severe COPD, respectively).
CONCLUSIONS: Emergency hospital care for eCOPD does not usually induce changes in inhaled maintenance treatment for COPD regardless of the duration of the hospital stay.

Entities:  

Keywords:  clinical practice; inward admission; quality of care; triple therapy

Mesh:

Substances:

Year:  2015        PMID: 26417965     DOI: 10.3109/15412555.2015.1043517

Source DB:  PubMed          Journal:  COPD        ISSN: 1541-2563            Impact factor:   2.409


  23 in total

1.  Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper.

Authors:  B R Celli; W MacNee
Journal:  Eur Respir J       Date:  2004-06       Impact factor: 16.671

2.  St. George's Respiratory Questionnaire: MCID.

Authors:  Paul W Jones
Journal:  COPD       Date:  2005-03       Impact factor: 2.409

3.  MMRM vs. LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets.

Authors:  Ohidul Siddiqui; H M James Hung; Robert O'Neill
Journal:  J Biopharm Stat       Date:  2009       Impact factor: 1.051

4.  A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD.

Authors:  Mario Cazzola; Filippo Andò; Pierachille Santus; Paolo Ruggeri; Fabiano Di Marco; Alessandro Sanduzzi; Maria D'Amato
Journal:  Pulm Pharmacol Ther       Date:  2006-07-07       Impact factor: 3.410

5.  [Bronchodilator efficacy of combined salmeterol and tiotropium in patients with chronic obstructive pulmonary disease].

Authors:  A Baloira Villar; C Vilariño Pombo
Journal:  Arch Bronconeumol       Date:  2005-03       Impact factor: 4.872

Review 6.  Minimal clinically important differences in COPD lung function.

Authors:  James F Donohue
Journal:  COPD       Date:  2005-03       Impact factor: 2.409

7.  Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial.

Authors:  Shawn D Aaron; Katherine L Vandemheen; Dean Fergusson; François Maltais; Jean Bourbeau; Roger Goldstein; Meyer Balter; Denis O'Donnell; Andrew McIvor; Sat Sharma; Graham Bishop; John Anthony; Robert Cowie; Stephen Field; Andrew Hirsch; Paul Hernandez; Robert Rivington; Jeremy Road; Victor Hoffstein; Richard Hodder; Darcy Marciniuk; David McCormack; George Fox; Gerard Cox; Henry B Prins; Gordon Ford; Dominique Bleskie; Steve Doucette; Irvin Mayers; Kenneth Chapman; Noe Zamel; Mark FitzGerald
Journal:  Ann Intern Med       Date:  2007-02-19       Impact factor: 25.391

8.  Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease.

Authors:  Tobias Welte; Marc Miravitlles; Paul Hernandez; Göran Eriksson; Stefan Peterson; Tomasz Polanowski; Romain Kessler
Journal:  Am J Respir Crit Care Med       Date:  2009-07-30       Impact factor: 21.405

9.  Performance of American Thoracic Society-recommended spirometry reference values in a multiethnic sample of adults: the multi-ethnic study of atherosclerosis (MESA) lung study.

Authors:  John L Hankinson; Steven M Kawut; Eyal Shahar; Lewis J Smith; Karen Hinckley Stukovsky; R Graham Barr
Journal:  Chest       Date:  2009-09-09       Impact factor: 9.410

10.  Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD.

Authors:  D Singh; J Brooks; G Hagan; A Cahn; B J O'Connor
Journal:  Thorax       Date:  2008-02-01       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.